Back to Search
Start Over
Effective Inhibition of MYC -Amplified Group 3 Medulloblastoma Through Targeting EIF4A1.
- Source :
-
Cancer management and research [Cancer Manag Res] 2020 Dec 03; Vol. 12, pp. 12473-12485. Date of Electronic Publication: 2020 Dec 03 (Print Publication: 2020). - Publication Year :
- 2020
-
Abstract
- Purpose: In medulloblastoma (MB), group 3 (G3) patients with MYC amplification tend to exhibit worse prognosis, thus creating a need for novel effective therapies. As the driver and crucial dependency for MYC -amplified G3-MB, MYC has been proven to be a prospective therapeutic target. Here, we aimed to identify novel effective therapeutic strategies against MYC -amplified G3-MB via targeting MYC translation.<br />Materials and Methods: Major components of translation initiation complex eIF4F were subjected to MB tumor dataset analysis, and EIF4A1 was identified to be a potential therapeutic target of MYC -amplified G3-MB. Validation was performed through genetic or pharmacological approaches with multiple patient-derived tumor models of MYC -amplified G3-MB in vitro and in vivo. Underlying mechanisms were further explored by Western blot, quantitative real-time PCR and mass spectrometry (MS) analyses.<br />Results: MB tumor datasets analyses showed that EIF4A1 was significantly up-regulated in G3-MB patients relative to normal cerebella, positively correlated with MYC in G3-MB at transcriptional level and a crucial cancer dependency in MYC -amplified G3-MB cells. Targeting EIF4A1 with a CRISPR/Cas9 approach or small-molecule inhibitor silvestrol effectively attenuated growth in multiple preclinical models of MYC -amplified G3-MB via blocking proliferation and inducing apoptosis. Mechanistically, EIF4A1 inhibition effectively impeded MYC expression at translational level, and its potency was positively associated with MYC level. Whole-proteome MS analysis of silvestrol-treated cells further unveiled other biological functions and pathways influenced by EIF4A1 inhibition.<br />Conclusion: Our investigation shows that interrupting MYC translation by EIF4A1 inhibition could be a potential effective therapeutic approach when treating patients with MYC -amplified G3-MB.<br />Competing Interests: The authors declare that there are no conflicts of interest in this work.<br /> (© 2020 Zhao et al.)
Details
- Language :
- English
- ISSN :
- 1179-1322
- Volume :
- 12
- Database :
- MEDLINE
- Journal :
- Cancer management and research
- Publication Type :
- Academic Journal
- Accession number :
- 33299354
- Full Text :
- https://doi.org/10.2147/CMAR.S278844